Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)

被引：0
|
作者：
Jove, M. [1 ]
Brana, I. [2 ]
Oliva Bernal, M. [3 ]
Hernando-Calvo, A. [4 ]
Erasun Lecuona, C. [5 ]
Assaf Pastrana, J. D. [6 ]
Bazan Peregrino, M. [7 ]
Mato-Berciano, A. [8 ]
Maliandi, M. V. [8 ]
Torres-Manjon, S. [9 ]
Martinez De Villareal, J. [10 ]
Real, F. X. [11 ]
Nuciforo, P. G. [12 ]
Alemany, R. [13 ]
Capella, G. [14 ]
Blasi, E. [15 ]
Blasco, C. [16 ]
Cascallo Piqueras, M. [17 ]
Mesia Nin, R. [18 ]
机构：
[1] Hosp Duran & Reynals, Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain
[2] Vall dHebron Univ Hosp, Mol Therapeut Res Unit, Barcelona, Spain
[3] Hosp Duran & Reynals, Div Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Barcelona, Spain
[4] Vall dHebron Inst Oncol VHIO, Mol Therapeut Res Unit, Early Drug Dev Unit, La Caixa Res UITM, Barcelona, Spain
[5] Hosp Duran & Reynals, Oncol Dept, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain
[6] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain
[7] VCN Biosci SL, R&D, Barcelona, Spain
[8] VCN Biosci SL, R&D, Sant Cugat Del Valles, Spain
[9] IDIBELL, Catalan Inst Oncol ICO, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Barcelona, Spain
[10] CNIO Ctr Nacl Invest Oncol, Epithelial Carcinogenesis Grp, Madrid, Spain
[11] CNIO Ctr Nacl Invest Oncol, Epithelial Carcinogenesis Grp, Mol Oncol Programme, Madrid, Spain
[12] Vall dHebron Inst Oncol VHIO, Mol Oncol Dept, Cellex Ctr, Barcelona, Spain
[13] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Spain
[14] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Hereditary Canc Program, Lhospitalet De Llobregat, Spain
[15] VCN Biosci SL, Regulatory, Sant Cugat Del Valles, Spain
[16] VCN Biosci SL, Clin Operat, Barcelona, Spain
[17] VCN Biosci SL, Clin Res, Barcelona, Spain
[18] Hosp Duran & Reynals, ICO Inst Catala Oncol, Dept Med Oncol, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1231P
引用
收藏
页码：S1112 / S1112
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.
    Segal, Neil Howard
    Ou, Sai-Hong Ignatius
    Balmanoukian, Ani Sarkis
    Fury, Matthew G.
    Massarelli, Erminia
    Brahmer, Julie R.
    Weiss, Jared
    Schoffski, Patrick
    Antonia, Scott Joseph
    Massard, Christophe
    Zandberg, Dan Paul
    Khleif, Samir
    Li, Xia
    Rebelatto, Marlon
    Steele, Keith
    Robbins, Paul B.
    Blake-Haskins, John A.
    Butler, Marcus O.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Interim analysis of the combination of durvalumab and cetuximab in a phase II trial of patients with recurrent and metastatic head and neck squamous cell carcinoma
    Gulati, Shuchi
    Palackdharry, Sarah
    Weatherford, Layne
    Wilson, Sarah
    Desai, Shireen
    Steele, Aubrey
    Riaz, Kashif
    Takiar, Vinita
    Draper, Trisha
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [44] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
  • [45] A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).
    Leidner, Rom S.
    Sukari, Ammar
    Chung, Christine H.
    Ohr, James
    Haigentz, Missak
    Cohen, Ezra E. W.
    Brown, Robert James
    Suzuki, Samuel
    Gorbatchevsky, Igor
    Fardis, Maria
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Phase 2 Trial of AT-101 in Combination With Docetaxel for Recurrent, Locally Advanced, or Metastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC) Management of Recurrent Head-and-Neck Squamous Cell Carcinoma
    Sacco, A.
    Nor, J.
    Belile, E.
    Sukari, A.
    Chepeha, D.
    Bradford, C.
    Eisbruch, A.
    Wolf, G.
    Urba, S.
    Worden, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 507 - 507
  • [48] Evaluation of systemic inflammatory response (SIR) markers in recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Pogorzelski, M.
    Hilser, T.
    Ting, S.
    Vossebein, I
    Gauler, T. C.
    Abendroth, A.
    Lang, S.
    Stuck, B.
    Abu-Jawad, J.
    Stuschke, M.
    Schmid, K. W.
    Schuler, M.
    Kasper, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 307 - 308
  • [49] Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)
    Jose Echarri, Maria
    Lopez-Martin, Ana
    Hitt, Ricardo
    CANCERS, 2016, 8 (03)
  • [50] Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Garralda, E.
    Villacampa Javierre, G.
    Feliu, B.
    Martinez, S.
    Gutierrez, R.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
12345